ENGN(ENGN)
ENGN
ANALYST COVERAGE9 analysts
HOLD
▲ +143.9%upside to target
L $2.00
Med $4.00consensus
H $28.00Key MetricsTTM
Market Cap$83.96M
Revenue TTM$0.00
Net Income TTM-$122.44M
Free Cash Flow-$103.78M
Gross Margin0.0%
Operating Margin0.0%
Net Margin0.0%
Return on Equity-55.8%
Return on Assets-36.3%
Debt / Equity0.12
Current Ratio11.75
EPS TTM$-1.82
PRICE
Prev Close
1.73
Open
1.70
Day Range1.64 – 1.76
1.64
1.76
52W Range1.40 – 12.25
1.40
12.25
2% of range
VOLUME & SIZE
Avg Volume
1.5M
FUNDAMENTALS
P/E Ratio
-0.7x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
TECHNICAL
RSI (14)
22
Oversold
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 100 days
Aug 31
ENGN News
About
No description available.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
Ronald H. W. CooperPresident, Chief Executive Officer & Director
Joan ConnollyChief Technology Officer
Anthony T. CheungCo-Founder & Chief Scientific Officer
Matthew BoydChief Regulatory Officer
Amy PottChief Global Commercialization Officer
Jill BuckChief Development Officer
Alex NicholsChief Strategy & Operations Officer
David Ryan DawsChief Financial Officer & Head of Business Development
Lee G. GiguereChief Legal Officer & Corporate Secretary
Hussein SweitiChief Medical Officer and Head of Research & Development
Tara PlaceSenior Vice President of Human Resources